RT Generic
T1 Monoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Pain
A1 Bravo, Lidia
A1 Llorca-Torralba, Meritxell
A1 Berrocoso, Esther
A1 Antonio Mico, Juan
K1 chronic pain
K1 neuropathic pain
K1 monoamines
K1 antidepressants
K1 noradrenaline
K1 serotonin
K1 Serotonin reuptake inhibitor
K1 Subtype messenger-rnas
K1 Histamine h-4 receptor
K1 Dorsal-root ganglion
K1 Induce peripheral antinociception
K1 Chronic constriction injury
K1 Spinal nerve ligation
K1 Double-blind
K1 Locus-coeruleus
K1 Rat model
AB Monoamines are involved in regulating the endogenous pain system and indeed, peripheral and central monoaminergic dysfunction has been demonstrated in certain types of pain, particularly in neuropathic pain. Accordingly, drugs that modulate the monaminergic system and that were originally designed to treat depression are now considered to be first line treatments for certain types of neuropathic pain (e.g., serotonin and noradrenaline (and also dopamine) reuptake inhibitors). The analgesia induced by these drugs seems to be mediated by inhibiting the reuptake of these monoamines, thereby reinforcing the descending inhibitory pain pathways. Hence, it is of particular interest to study the monoaminergic mechanisms involved in the development and maintenance of chronic pain. Other analgesic drugs may also be used in combination with monoamines to facilitate descending pain inhibition (e.g., gabapentinoids and opioids) and such combinations are often also used to alleviate certain types of chronic pain. By contrast, while NSAIDs are thought to influence the monoaminergic system, they just produce consistent analgesia in inflammatory pain. Thus, in this review we will provide preclinical and clinical evidence of the role of monoamines in the modulation of chronic pain, reviewing how this system is implicated in the analgesic mechanism of action of antidepressants, gabapentinoids, atypical opioids, NSAIDs and histaminergic drugs.
PB Frontiers media sa
YR 2019
FD 2019-11-26
LK http://hdl.handle.net/10668/19237
UL http://hdl.handle.net/10668/19237
LA en
DS RISalud
RD Apr 6, 2025